Literature DB >> 18656534

Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2.

Eva M del Amo1, Arto Urtti, Marjo Yliperttula.   

Abstract

LAT1 and LAT2 are heterodimeric large amino acid transporters that are expressed in various tissues, including the intestinal wall, blood-brain barrier, and kidney. These transporters consist of membrane spanning light chain and heavy chain, and they act as 1:1 exchangers in concert with other amino acid transporters. Only a few drugs (less than 10) are substrates of LAT1 and LAT2, including L-DOPA, alpha-methyldopa, melphalan, and gabapentin. The mechanisms and substrates have been mostly elucidated using mammalian cells and Xenopus oocytes. The in vivo relevance of LAT1 and LAT2 in pharmacokinetics is obscure, because contradictory findings have been reported. It is difficult to make quantitative pharmacokinetic conclusions about LAT1 and LAT2. This is due to the possible involvement of other transporters (including cross-linked heterodimers of light chain with different heavy chains, other overlapping transporters, for example TAT1), competing endogenous amino acids, and saturation phenomena. This review presents the current functional knowledge on LAT1 and LAT2 with emphasis on their potential involvement in pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656534     DOI: 10.1016/j.ejps.2008.06.015

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  109 in total

Review 1.  In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use.

Authors:  Hans C Helms; N Joan Abbott; Malgorzata Burek; Romeo Cecchelli; Pierre-Olivier Couraud; Maria A Deli; Carola Förster; Hans J Galla; Ignacio A Romero; Eric V Shusta; Matthew J Stebbins; Elodie Vandenhaute; Babette Weksler; Birger Brodin
Journal:  J Cereb Blood Flow Metab       Date:  2016-02-11       Impact factor: 6.200

2.  Alterations in the proteome of the NHERF2 knockout mouse jejunal brush border membrane vesicles.

Authors:  M Donowitz; S Singh; P Singh; M Chakraborty; Y Chen; R Murtazina; M Gucek; R N Cole; N C Zachos; F F Salahuddin; O Kovbasnjuk; N Broere; W G Smalley-Freed; A B Reynolds; A L Hubbard; U Seidler; E Weinman; H R de Jonge; B M Hogema; X Li
Journal:  Physiol Genomics       Date:  2011-03-22       Impact factor: 3.107

3.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

Review 4.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Protein kinase C activation upregulates human L-type amino acid transporter 2 function.

Authors:  Hanae Morio; Yoshie Reien; Yuri Hirayama; Hirofumi Hashimoto; Naohiko Anzai
Journal:  J Physiol Sci       Date:  2021-03-31       Impact factor: 2.781

6.  An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Linda Grasfeder; Michael R Zalutsky; Bennett Chin
Journal:  Appl Radiat Isot       Date:  2011-05-19       Impact factor: 1.513

Review 7.  SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers.

Authors:  Marilyn E Morris; Vivian Rodriguez-Cruz; Melanie A Felmlee
Journal:  AAPS J       Date:  2017-06-29       Impact factor: 4.009

Review 8.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

9.  Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Yijun Pan; Kotaro Omori; Izna Ali; Masanori Tachikawa; Tetsuya Terasaki; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2018-08-22       Impact factor: 4.939

10.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.